Amunix Pharmaceuticals

History

2021: Sanofi bought Amunix Pharmaceuticals for $1.2 billion

On December 21, 2021, Sanofi announced the purchase of Amunix Pharmaceuticals, an immuno-oncological drug company for $1.2 billion.

The French drug manufacturer will pay $1 billion in advance and up to $225 million if the development goals of the purchased company are achieved, the company said in a statement.

Amunix, based in Mountain View, Calif., is developing treatments aimed at using the immune system to fight cancer. Sanofi said the drugs this company is developing are "great for strategic purpose" with a focus on developing immuno-oncology therapies.

Sanofi acquired Amunix Pharmaceuticals for $1.2 billion

The deal will give Sanofi access to patented Amunix platform technologies that can be used to detect and develop transforming T cell activators and cytokine drugs to treat cancer patients. Sanofi will also take on Amunix's promising assortment of T cell activators and cytokine drugs, which includes AMX-818, a disguised HER2-directed T lymphocyte activator. It is expected that the remedy for breast cancer will enter the clinic in early 2022.

This acquisition demonstrates our continued commitment to investing in promising research and discovery platforms, said Jon Reed, MD, head of research and development at Sanofi.

The company expects to complete the deal with Amunix in the first quarter of 2022. Under the leadership of Chief Executive Officer Paul Hudson, Sanofi has embarked on acquisitions to catch up with its competitors in terms of innovation and potential revenue.

Sanofi, forced to revive drug production and still overcoming failures in the race for the COVID vaccine, has been busy making deals all of 2021. In August, the manufacturer announced the purchase of mRNA developer Translate Bio for $3.2 billion. In September, Sanofi entered into another major deal to buy Kadmon Holdings, an American company specializing in the treatment of immune disorders, fibrous diseases and cancer, for $1.9 billion.^[1]

Notes